Actively Recruiting
Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors
Led by Wake Forest University Health Sciences · Updated on 2025-12-15
60
Participants Needed
1
Research Sites
55 weeks
Total Duration
On this page
Sponsors
W
Wake Forest University Health Sciences
Lead Sponsor
T
The Ambrose Monell Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to find out if taking a Fisetin supplement can decrease fatigue among older cancer survivors.
CONDITIONS
Official Title
Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of cancer diagnosed more than 12 months before enrollment, excluding non-melanoma skin cancer, with no current disease evidence
- Eligible solid tumor cancers include Stage 1-3 breast, lung, head and neck, colorectal, anal, prostate, melanoma, bladder/ureteral, esophageal, gastric, pancreatic, kidney, liver/biliary, uterine, cervical, ovarian, sarcoma
- Eligible hematologic cancers include lymphoma, multiple myeloma, and leukemia in remission
- Prior cancer treatments can include surgery, radiation, chemotherapy, hormonal, immunotherapy, or biologic therapies
- Completed all anti-cancer treatments more than 6 months but less than 5 years prior to enrollment
- Self-reported fatigue defined as feeling "somewhat," "quite a bit," or "very much" fatigued during the past seven days
- Ability to walk without assistance from another person (use of cane or walker is allowed)
- Ability to understand and willing to sign informed consent (or via legally authorized representative)
You will not qualify if you...
- Unable or unwilling to provide informed consent
- Female patients must be postmenopausal for at least 1 year if of childbearing potential
- Prisoners, institutionalized people, or vulnerable populations such as individuals with dementia
- Currently taking warfarin or Coumadin
- Taking steroids regularly or within the last two weeks
- Taking medications sensitive to CYP enzymes or strong inhibitors/inducers of CYP3A4 unless dosing can be safely modified or held during treatment periods
- Uncontrolled high blood pressure (systolic >170 or diastolic >100 mmHg)
- Uncontrolled pleural/pericardial effusions or ascites
- Active cancer or ongoing cancer treatment including oral anti-estrogen therapy, immunotherapy, or biologic therapy
- Men receiving androgen deprivation therapy
- Symptomatic congestive heart failure
- Lung disease requiring oxygen
- End stage renal disease requiring dialysis
- Unable to swallow capsules
- Chronic nausea or diarrhea occurring at least once per week
- Diagnosis of dementia
- Uncontrolled illnesses such as infection, unstable angina, arrhythmia, or psychiatric/social issues limiting study compliance
- Untreated hypothyroidism
- Allergy to fisetin
- HIV infection
- Active untreated hepatitis B or C
- Active invasive fungal infection
- Unwilling to provide consent including access to electronic health records
- Judged unsuitable for the trial by research team
- Abnormal lab values including low blood counts, elevated liver enzymes, low kidney function, or very high fasting glucose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Atrium Health Wake Forest Baptist Hospital
Winston-Salem, North Carolina, United States, 27157
Actively Recruiting
Research Team
K
Kimberly Kennedy
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here